Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Amicus Therapeutics (FOLD) Leases (2019 - 2025)

Amicus Therapeutics filings provide 7 years of Leases readings, the most recent being $21.1 million for Q4 2025.

  • On a quarterly basis, Leases fell 5.12% to $21.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $21.1 million, a 5.12% decrease, with the full-year FY2025 number at $21.1 million, down 5.12% from a year prior.
  • Leases hit $21.1 million in Q4 2025 for Amicus Therapeutics, down from $21.5 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $30.4 million in Q2 2022 to a low of $20.6 million in Q4 2021.
  • Median Leases over the past 5 years was $22.8 million (2024), compared with a mean of $24.7 million.
  • Biggest five-year swings in Leases: tumbled 31.19% in 2021 and later skyrocketed 43.47% in 2022.
  • Amicus Therapeutics' Leases stood at $20.6 million in 2021, then skyrocketed by 43.47% to $29.5 million in 2022, then decreased by 10.91% to $26.3 million in 2023, then decreased by 15.33% to $22.3 million in 2024, then decreased by 5.12% to $21.1 million in 2025.
  • The last three reported values for Leases were $21.1 million (Q4 2025), $21.5 million (Q3 2025), and $22.0 million (Q2 2025) per Business Quant data.